NCT06815965 - A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions

Dementia With Lewy Bodies (DLB)

Interventions

DRUG

neflamapimod

Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase 14 (p38α). It is administered orally in 40 mg capsules.

Trial Locations (2)

67000

Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg), Strasbourg

75010

Hôpital Lariboisière - APHP; Centre de Neurologie Cognitive, Paris